Medicamen Biotech Limited (NSE:MEDICAMEQ)

Market Cap	3.12B -45.7%
Revenue (ttm)	2.01B +19.9%
Net Income	96.41M +35.6%
EPS	7.11 +27.2%
Shares Out	n/a
PE Ratio	32.35
Forward PE	n/a
Dividend	1.00 (0.39%)
Ex-Dividend Date	Sep 19, 2025

Volume	46,675
Open	245.10
Previous Close	245.65
Day's Range	242.05 - 248.70
52-Week Range	216.95 - 447.65
Beta	0.62
Analysts	n/a
Price Target	n/a
Earnings Date	May 27, 2026

About Medicamen Biotech

Medicamen Biotech Limited, a pharmaceutical company, research, develops, manufactures, markets, sells, and distributes pharmaceutical formulations in India and internationally. The company offers drugs in various forms, including tablet, capsule, syrups, oral solution, and drops. Its products are used in therapeutic areas comprising cancer care, cardiology, CNS, diabetology, anti-infective, anti-malarials, vitamins, antibiotics, and supplements, other generics, and pain management. The company was incorporated in 1993 and is based in New Delhi,...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 376
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: MEDICAMEQ

Financial Performance

In fiscal year 2026, Medicamen Biotech's revenue was 2.01 billion, an increase of 19.90% compared to the previous year's 1.68 billion. Earnings were 96.41 million, an increase of 35.64%.